ClinicalTrials.gg
CompletedNCT07519278Updated Apr 14, 2026

Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects

A Phase 1 interventional study of Test formulation(pramipexole dihydrochloride extended-release tablets) and Reference formulation(MIRAPEX ER®) in Healthy, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 9 years after the study started (first participant enrolled Mar 2017, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study compared pramipexole dihydrochloride extended-release tablets (Test formulation) by Haisco Pharmaceutical Group Co., Ltd. with the reference formulation (MIRAPEX ER®,Boehringer Ingelheim GmbH of Germany) to evaluate the bioequivalence of single dose in Chinese healthy subjects under fasting and fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged 18 years or older (inclusive);
  2. Body weight ≥ 50 kg for males and ≥ 45 kg for females, with (BMI) between 19 and 26 (inclusive);
  3. No abnormalities in vital signs, physical examination, laboratory tests, 12-lead (ECG), chest X-ray (posteroanterior view), or abdominal ultrasound at screening;
  4. All subjects must be willing to use appropriate measures from the screening period, throughout the trial drug administration period, and until one month after drug discontinuation;
  5. Subjects must understand and comply with the study procedures, voluntarily participate, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with serious systemic diseases, infectious diseases, or mental disorders that, in the investigator's opinion, make them unsuitable for participation in this study;
  2. History of abnormalities or family history of long syndrome (grandparents, parents, and siblings);
  3. Known or suspected history of allergy to the drug or drugs with a similar chemical structure;
  4. Presence of conditions that may affect drug absorption, distribution, metabolism, or excretion, including but not limited to any of the following:

    • History of inflammatory bowel disease, gastritis, gastrointestinal ulcer, gastrointestinal bleeding, or other clinically significant gastrointestinal abnormalities.
    • History of major gastrointestinal surgery (e.g., gastrectomy, gastrointestinal anastomosis, enterectomy, gastric bypass, gastric partitioning, or gastric banding).
    • History of clinically significant renal disease or impaired renal function, or laboratory abnormalities at screening.
    • Liver disease or laboratory abnormalities indicative of clinically significant hepatic impairment at screening.
  5. Subjects with positive test results for (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody, or syphilis antibody;
  6. History of drug abuse or alcohol abuse within 12 months prior to screening (consuming more than 2 units of alcohol per day or more than 14 units per week; 1 unit = 355 mL beer, 30 mL liquor, or 150 mL wine);
  7. Average daily smoking of more than 5 cigarettes within 3 months prior to screening (assessed by interview at screening), or inability to refrain from smoking during the entire study period;
  8. Blood donation or blood loss of ≥ 400 mL within 3 months prior to screening;
  9. Participation in another clinical trial within 3 months prior to screening;
  10. Use of any prescription medication within 4 weeks prior to screening;
  11. Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines within 2 weeks prior to screening. Refusal to discontinue any beverages or foods containing xanthines, such as caffeine (coffee, tea, cola, chocolate, etc.), from 48 hours before dosing until the end of the study;
  12. Pregnant or breastfeeding women;
  13. History of orthostatic hypotension, sudden vertigo, or transient syncope;
  14. Subjects deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Test formulation

    pramipexole dihydrochloride extended-release tablets (0.375 mg/table),Manufacturer: Haisco Pharmaceutical Group Co., Ltd

    Drug: Test formulation(pramipexole dihydrochloride extended-release tablets)

  • Experimental
    Reference formulation

    pramipexole dihydrochloride extended-release tablets (MIRAPEX ER®,0.375 mg/table) Manufacturer: Boehringer Ingelheim GmbH of Germany

    Drug: Reference formulation(MIRAPEX ER®)

Interventions

  • DrugTest formulation(pramipexole dihydrochloride extended-release tablets)

    Test formulation (pramipexole dihydrochloride extended-release tablets, Haisco Pharmaceutical Group Co., Ltd), A single oral dose of 0.375 mg, taken with 240mL of water

  • DrugReference formulation(MIRAPEX ER®)

    Reference formulation (pramipexole dihydrochloride extended-release tablets, Boehringer Ingelheim GmbH of Germany), A single oral dose of 0.375 mg, taken with 240mL of water

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Concentration)

    The pharmacokinetic parameters of pramipexole in plasma

    Time frame: From the start of administration to 72 hours post-dose

  2. AUC(0-t) (Area Under the Concentration-Time Curve from time 0 to time t)

    The pharmacokinetic parameters of pramipexole in plasma

    Time frame: From the start of administration to 72 hours post-dose

  3. AUC(0-∞) (Area Under the Concentration-Time Curve from time 0 to infinity)

    The pharmacokinetic parameters of pramipexole in plasma

    Time frame: From the start of administration to 72 hours post-dose

Secondary outcomes

  1. AEs (Adverse Events)

    The incidence and severity of AEs

    Time frame: From the time of signing ICF (Informed Consent Form) to the end of follow-up,up to 10 days

07

Study locations

1 site
  • The General Hospital of Western Theater Command PLA
    Chengdu, Sichuan, China
08

References and documents

Publications

  • Chen Q, Shi HQ, Chen YF, Zhang W, Ye L, Li YM, Hu TT. Comparative pharmacokinetics for bioequivalence of pramipexole dihydrochloride extended-release tablets in fasting and fed Chinese healthy volunteers: a randomized, open-label, single-dose, crossover study. BMC Pharmacol Toxicol. 2026 May 11;27(1):94. doi: 10.1186/s40360-026-01144-w. PubMed 42116205 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Apr 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Mar 16, 2017
Primary completionActual
Apr 11, 2017
CompletionActual
Feb 12, 2018
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519278
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Mar 16, 2017
Primary completion
Apr 11, 2017
Completion
Feb 12, 2018
Last update
Apr 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion